Elan reports third quarter revenues increased by 53% boosted by Tysabri sales; Operating loss fell to $39.3m
Oct 23rd, 2008 | By Finfacts Ireland Business & Finance Portal | Category: News worldwide
Elan, the Irish drugs firm, reported today that its third quarter revenues increased by 53% to $270.1m, compared to revenues of $176.6m in the third quarter of 2007. The operating loss of $39.3m for the three month period fell from $63.6m for the third quarter in 2007.